DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > School of Medicine > Bulletin > Acta Medica Nagasakiensia > Volume 52, No. 2 >

Molecular Targeting Therapy for Renal Cell Carcinoma: Current Status and Our Suggestion


File Description SizeFormat
acta52_02_39.pdf493.58 kBAdobe PDFView/Open

Title: Molecular Targeting Therapy for Renal Cell Carcinoma: Current Status and Our Suggestion
Authors: Miyata, Yasuyoshi
Issue Date: Jun-2007
Citation: Acta medica Nagasakiensia. 2007, 52(2), p.39-43
Abstract: Renal cell carcinoma (RCC) is a common urological malignancy. Patients with low stage RCC have a good prognosis by radical operation. On the other hand, advanced RCC do not respond to most treatment and survival is poor in such patients. Some immuno-therapies were performed to patients with advanced RCC, but the patients who obtained clinically meaningful benefit were very limited. To identify promising targets for novel therapeutic agents, numerous investigations have been carried out regarding the molecular mechanisms of tumor growth and progression. Recently, some molecular-targeting therapies, including anti-vascular endothelial growth factor agent, have demonstrated to prolong survival in phase II and III trials. However, such treatments also showed limited anti-tumoral effects and various severe side effects beyond expectation. These results necessitate more extensive and profound knowledge of pathological features to discuss the treatment strategies for RCC. We have been investigating the molecular mechanism of cancer cell invasion and metastasis in patients with RCC for last few years, and we have obtained several new findings and information about them. In this article, we will describe clinical and pathological significance of several invasion-related and/or angiogenesis-related factors, such as matrix metalloproteinases, thrombospondin, and hepatocyte growth factor/c-Met. These factors are well known to regulate invasive function, angiogenesis, and cancer cell proliferation in various malignant tumors, and animal experiments demonstrated that some selective molecular inhibitors of them could inhibit tumorigenicity and tumor development. Our studies show that some molecular inhibitors may provide a novel therapeutic approach to RCC.
Keywords: Moleculartargettherapy / Thrombospondin / Matrixmetalloproteinases / Hepatocytegrowthfactorreceptor / Renalcellcarcinoma
URI: http://hdl.handle.net/10069/9392
ISSN: 00016055
Relational Links: http://joi.jlc.jst.go.jp/JST.JSTAGE/amn/52.39
Type: Departmental Bulletin Paper
Text Version: publisher
Appears in Collections:Volume 52, No. 2

Citable URI : http://hdl.handle.net/10069/9392

All items in NAOSITE are protected by copyright, with all rights reserved.

 

Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace